A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Details
Age
Child to Adult
Locations
Childrens Hospital Colorado
Principal Investigator
KELLY MALONEY
Study ID
Protocol Number: 19-2631
More information available at ClinicalTrials.gov: NCT03959085
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers